Literature DB >> 17400297

Genomics in multiple sclerosis--current state and future directions.

Manuel Comabella1, Roland Martin.   

Abstract

Microarray-based gene expression profiling of large numbers of genes or even the whole genome has only recently become possible. Several studies have employed this technology in multiple sclerosis (MS) and its animal model, experimental allergic encephalomyelitis (EAE), and although results are promising, microarray-based genomics research is still viewed with skepticism. It is often negatively perceived as a fishing expedition rather than a discovery-oriented effort that takes into account the immense complexity of diseases such as MS. Besides these conceptual concerns, technical reproducibility and the strategies to analyze and interpret the massive amounts of data present problems that can cause considerable variability between studies. In this review, we summarize existing data from different gene expression profiling studies that have been conducted in MS and EAE, discuss potential problems and propose future directions for the use of microarrays in MS.

Entities:  

Mesh:

Year:  2007        PMID: 17400297     DOI: 10.1016/j.jneuroim.2007.02.009

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  23 in total

1.  Comparative gene expression analysis in mouse models for multiple sclerosis, Alzheimer's disease and stroke for identifying commonly regulated and disease-specific gene changes.

Authors:  Vivian Tseveleki; Renee Rubio; Sotiris-Spyros Vamvakas; Joseph White; Era Taoufik; Edwige Petit; John Quackenbush; Lesley Probert
Journal:  Genomics       Date:  2010-05-07       Impact factor: 5.736

2.  Substrain differences reveal novel disease-modifying gene candidates that alter the clinical course of a rodent model of multiple sclerosis.

Authors:  Leslie E Summers deLuca; Natalia B Pikor; Jennifer O'Leary; Georgina Galicia-Rosas; Lesley A Ward; Dustin Defreitas; Trisha M Finlay; Shalina S Ousman; Lucy R Osborne; Jennifer L Gommerman
Journal:  J Immunol       Date:  2010-02-19       Impact factor: 5.422

3.  Enhancing the ability of experimental autoimmune encephalomyelitis to serve as a more rigorous model of multiple sclerosis through refinement of the experimental design.

Authors:  Mitchell R Emerson; Ryan J Gallagher; Janet G Marquis; Steven M LeVine
Journal:  Comp Med       Date:  2009-04       Impact factor: 0.982

4.  Positive family history of idiopathic sudden sensorineural hearing loss.

Authors:  A Gäckler; A K Eickelmann; D Brors; S Dazert; J T Epplen; E Kunstmann
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-07-01       Impact factor: 2.503

Review 5.  Extracellular cues influencing oligodendrocyte differentiation and (re)myelination.

Authors:  Natalie A Wheeler; Babette Fuss
Journal:  Exp Neurol       Date:  2016-03-23       Impact factor: 5.330

Review 6.  Body fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the future.

Authors:  Itay Raphael; Johanna Webb; Olaf Stuve; William Haskins; Thomas Forsthuber
Journal:  Expert Rev Clin Immunol       Date:  2014-12-18       Impact factor: 4.473

Review 7.  Biomarkers in Multiple Sclerosis.

Authors:  Anu Paul; Manuel Comabella; Roopali Gandhi
Journal:  Cold Spring Harb Perspect Med       Date:  2019-03-01       Impact factor: 6.915

Review 8.  Neuroprotective effects of the complement terminal pathway during demyelination: implications for oligodendrocyte survival.

Authors:  Cosmin A Tegla; Cornelia Cudrici; Violeta Rus; Takahiro Ito; Sonia Vlaicu; Anil Singh; Horea Rus
Journal:  J Neuroimmunol       Date:  2009-07-04       Impact factor: 3.478

Review 9.  Defining and scoring response to IFN-β in multiple sclerosis.

Authors:  Maria Pia Sormani; Nicola De Stefano
Journal:  Nat Rev Neurol       Date:  2013-07-30       Impact factor: 42.937

10.  Proteome profiling in murine models of multiple sclerosis: identification of stage specific markers and culprits for tissue damage.

Authors:  Ralf A Linker; Peter Brechlin; Sarah Jesse; Petra Steinacker; D H Lee; Abdul R Asif; Olaf Jahn; Hayrettin Tumani; Ralf Gold; Markus Otto
Journal:  PLoS One       Date:  2009-10-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.